German pharma major Bayer has confirmed its plans to localize 50% of its drugs in Russia by 2025, according to recent statements by Niels Hessmann, general representative of Bayer in Russia and the CIS region, reports The Pharma Letter’s local correspondent. 9 July 2019
Anglo-Swedish pharma major AstraZeneca is considering initiating massive exports of its Russian-made drugs, particularly those produced at the capacities of its local plant in the Kaluga region, according to recent statements by Leonard Wang, executive vice president of AstraZeneca International Markets and head of AstraZeneca China. 9 July 2019
Myelodysplastic syndromes (MDS) are a group of disorders that arise from the inadequate functioning of the bone marrow (the spongy material in bones with stem cells), particularly in blood cell production. 9 July 2019
Bispecific antibodies are artificial proteins that contain two different antigen-binding sites, allowing them to bind to two different types of antigens at the same time.1 As a result, bispecific antibodies can target several molecules, which potentially provides an advantage over utilizing combination therapies or mixtures of various antibodies, writes Dr Nicola Davies in her exclusive blog for The Pharma Letter. 8 July 2019
A moderation in pricing pressure for the US market, new launches and market share gains for existing products along with consolidation benefits are set to drive growth for India’s pharmaceutical industry in fiscal year 2020, reports The Pharma Letter’s local correspondent. 8 July 2019
Mexico’s pharmaceutical industry – renowned for the quality and reliability of its medicines production – sees South America and Europe as its main export markets. 8 July 2019
For biosimilar companies in Europe, data showing the savings that their products are delivering are becoming just as important as findings on biosimilarity. 5 July 2019
IBM Watson Health has seen that being thought of as a pioneering company in applying artificial intelligence (AI) in healthcare can have its pros and cons, from a publicity point of view. 2 July 2019
The Russian government has put forward an initiative for the compulsory licensing of patented drugs produced for exports, so that Russian companies can manufacture and sell drugs protected by a patent, according to recent statements by the press service of the Russian federal government, reports The Pharma Letter’s local correspondent. 1 July 2019
Close on the heels of an alert raised by the US Food and Drug Administration and Health Canada regarding the safety of sodium glucose cotransporter-2 (SGLT-2) inhibitors from Johnson & Johnson (NUSE: JNJ) and Germany-based Boehringer Ingelheim, the Drug Controller General of India (DCGI) has asked drug manufacturers to carry a warning label on all new diabetes drugs, reports The Pharma Letter’s India correspondent. 1 July 2019
Global drugmakers operating in the Russian market are considering optimizing of their local ranges this year, mainly as a result of the introduction of new labeling practices in Russia, starting from January, 1 2020, and with the associated increase of their costs, reports The Pharma Letter’s local correspondent. 1 July 2019
Gross domestic product (GDP) in Japan is about $5 trillion, and the country’s pharmaceutical market is one of the largest in the world, with figures from the Ministry of Health, Labour and Welfare (MHLW) indicating a market value of about $95 billion, including non-prescription medications. 28 June 2019
A new cholera vaccine, in Phase III trials, is expected to be six times cheaper than the three currently available in India, making it more cost-effective for inclusion in public health programs, reports The Pharma Letter’s local correspondent. 27 June 2019
Ayesha Raghib, associate at IP law firm Powell Gilbert, provides an Expert View on the imminent introduction of legislation that could prompt a spike in pharma litigation. 27 June 2019
Europe's biggest privately-held biotech BioNTech has been in the news recently, with reports the company could be about to raise just shy of a billion dollars in a US listing. 25 June 2019
The share of domestic drugs in the overall sales structure in the Russian pharmaceutical market reached 58% this year, which is a historical record for Russia in the last 30 years, according to recent statistics published by the Russian Ministry of Health and some local analytical agencies in the field of pharmaceutics, reports The Pharma Letter’s local correspondent. 25 June 2019
The healthcare industry is at an inflection point with the market now preparing for more cell and gene therapies to be approved, writes Ana Stojanovska, vice president of Commercial Consulting at Xcenda, in an Expert View piece. 21 June 2019
For Belgium-based drugmaker UCB, EULAR 2019 came at a good time to shed further new light on bimekizumab – which the company itself is billing as its pipeline molecule – in a couple of the indications in which it is showing significant promise. 21 June 2019
In the wake of the 21st Century Cures Act (Cures Act), the US Food and Drug Administration was tasked with exploring how real-world evidence (RWE) could be incorporated into regulatory decision-making. 20 June 2019
F2G’s September $100m funding round provides the company with crucial funds to
renavigate approval of its lead drug, olorofim. The substantial financing also
highlights the paucity of novel antifungal products in the clinic. 3 October 2024
Timing can be crucial in biotech, and any company that can help optimize radiopharmaceuticals to fight cancer is likely to a hot property right now, given the recent popularity of the field among investors and drugmakers. 2 October 2024
As stakeholders in the pharmaceutical industry, we all have a responsibility to ensure life-saving treatments promptly and safely reach patients regardless of where they live. To this end, by integrating early access programs and other less conventional strategies into a company’s business model for drug distribution, patients who are suffering from life-threatening conditions can gain access to needed treatments in regions where there is a lack of drug accessibility, while at the same time offering benefits to pharmaceutical companies. 2 October 2024
The Russian government has finalized the rules for granting preference to domestic drugs in public procurements, which will come into force in 2025. 1 October 2024
A Feature on M&A, licensing and partnerships hotting up in inflammatory diseases as new targets present new opportunities for future growth. 30 September 2024
India is set to complete 50 new greenfield pharma manufacturing plants in the next two years under its Production-linked Incentive (PLI) scheme for pharma and medical devices. 30 September 2024
The number of clinical trials of new drugs in Russia is steadily declining, which could be mainly related with the overall reduction of investment activities in the local pharmaceutical market, reports The Pharma Letter’s local correspondent. 30 September 2024
Pharmaceutical laboratories, institutions, guilds and medical federations have taken on the task of designing programs to end health illiteracy in order to have informed, educated, knowledgeable and empowered communities where their health and wellbeing are concerned. 19 September 2024
Oligonucleotide therapeutics are rapidly emerging as a promising class of drugs capable of addressing a variety of genetic and complex diseases by targeting RNA sequences.1 16 September 2024
The protection of intellectual property (IP) rights of foreign pharmaceutical companies in Russia remains complex situation, according to recent statements by Konstantin Panurovsky, legal director of AstraZeneca’s Russian subsidiary, reports The Pharma Letter’s local correspondent. 13 September 2024
The Russian Ministry of Health wants to speed registration of drugs that are not localized in the Russian Federation at the time of the application submitted by domestic pharmaceutical companies, explaining such changes by "unpredictable geopolitical situation," reports The Pharma Letter’s local correspondent. 12 September 2024
NewCo, a relatively new business model that involves a joint venture (JV) between a biotech and a group of investors to bring the biotech’s promising assets to the global market, is gaining popularity among Chinese biotechs, who traditionally rely on out-licensing deals to capitalize assets, s 11 September 2024
The upcoming European Society for Medical Oncology (ESMO) Congress 2024 should provide a reminder—if it were needed—of the pace of innovation in the development of new medicines for cancer. 10 September 2024
A significant drop has been noticed in the prices of active pharmaceutical ingredients (APIs), bringing much-needed relief to the pharmaceutical industry and potentially translating to lower drug costs for consumers. 9 September 2024
Amid an explosion in investment and development milestones seen over the past decade, the age of radiopharmaceuticals as both diagnostics and as therapeutics is very much arriving. 5 September 2024
German pharma major Bayer has filed a lawsuit against the Russian drugmaker Promomed to protect the patent rights for Xarelto (rivaroxaban), its treatment for stroke prevention which is the best-selling drug in the Russian market at present, The Pharma Letter’s local correspondent reports. 2 September 2024
In a major crackdown, the Indian government has imposed an immediate ban on 156 fixed-dose combination (FDC) drugs, including commonly used antibiotics, pain relievers,and multivitamins. 27 August 2024
A pre-clinical stage biopharmaceutical group developing new medicines and treatments to treat blood and autoimmune disease and to bring the curative power of bone marrow transplantation to a greater number of patients suffering from otherwise incurable life-threatening diseases.
Sign up to receive email updates Join industry leaders for a daily roundup of biotech & pharma news